Gastroesophageal Junction Adenocarcinoma Clinical Trials

179 clinical trials for Gastroesophageal Junction Adenocarcinoma across international registries, including 44 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma — RECRUITING · PHASE3
• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread — RECRUITING · PHASE1
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection — RECRUITING
• NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer — RECRUITING · PHASE1
• A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors — RECRUITING · PHASE1
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis — RECRUITING · PHASE1
• Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer — RECRUITING · PHASE2
• A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment — RECRUITING · PHASE3
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors — RECRUITING · PHASE1
• Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence — RECRUITING · PHASE2
• Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 — RECRUITING · PHASE3
• A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer — RECRUITING · PHASE2
• Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity — RECRUITING · PHASE2
• TAIC FOLFOX for Locally Advanced G/GEJA — RECRUITING · PHASE2
• A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer — RECRUITING · PHASE3
• Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program — RECRUITING · PHASE2
• IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma — RECRUITING · PHASE2
• Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma — RECRUITING · PHASE2
• Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study — RECRUITING · PHASE2
• Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma — RECRUITING
• Registry Platform Gastric/Esophageal Cancer (SAPHIR) — RECRUITING
• A Study of KK2269 in Adult Participants With Solid Tumors — RECRUITING · PHASE1
• Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma — RECRUITING · PHASE1
• SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure — RECRUITING · PHASE2
• Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma — RECRUITING · PHASE1
• A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma — RECRUITING · PHASE3
• Folfox+Irinotecan+Chemort In Esophageal Cancer — RECRUITING · PHASE2
• Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies — RECRUITING · PHASE1
• To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma — RECRUITING
• Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma — RECRUITING · PHASE2
• APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors — RECRUITING · PHASE2
• Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer. — RECRUITING
• Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer — RECRUITING · PHASE2
• A Multicenter Cancer Biospecimen Collection Study — RECRUITING
• BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma. — RECRUITING · PHASE1
• HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) — RECRUITING · PHASE3
• Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression — RECRUITING · PHASE2
• AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer — RECRUITING · PHASE2
• DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy — RECRUITING · PHASE2
• Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma — RECRUITING · PHASE2
• Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. — RECRUITING · PHASE2
• Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer — RECRUITING · PHASE2
• Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer — RECRUITING · PHASE2
• Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery — SUSPENDED · PHASE2
• XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. — ACTIVE_NOT_RECRUITING · PHASE1
• Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers — ACTIVE_NOT_RECRUITING
• A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma — ACTIVE_NOT_RECRUITING · PHASE2

Refine this search